Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Drug: Savolitinib with Osimertinib for EGFR-Mutated, MET-Amplified NSCLC
Savolitinib-osimertinib significantly prolonged progression-free survival compared to chemotherapy in EGFR mutation-positive, MET-amplified Chinese NSCLC patients. The combination
New Indication: Ribociclib + Letrozole for Low-Grade Serous Ovarian Cancer
Ribociclib plus letrozole achieved a 30.6% overall response rate, with a median progression-free survival of 14.5 months and median overall survival of 44.5 months. The regimen dem
New Reference: Pirtobrutinib vs. Ibrutinib in CLL
Pirtobrutinib was shown to be non-inferior to ibrutinib in terms of overall response rate and had a more favorable safety profile, with lower rates of adverse cardiac events. The s
New Indication: Pirtobrutinib for Untreated CLL without del(17p)
Pirtobrutinib showed superior progression-free survival compared to bendamustine plus rituximab with a hazard ratio of 0.199. It was well tolerated with significantly fewer adverse
New Protocol: Neoadjuvant Low-dose Pembrolizumab for Triple-Negative Breast Cancer
The PLANeT trial demonstrated that the addition of low-dose pembrolizumab (50 mg every 6 weeks) to standard chemotherapy significantly increased pathological complete response rate
New Reference: Adjuvant Nivolumab for Muscle-Invasive Bladder Cancer
The study found that adjuvant nivolumab significantly improved disease-free survival compared to placebo in patients with high-risk muscle-invasive urothelial carcinoma. The analys
New Protocol: Adjuvant Nivolumab with CISplatin Concurrently with Radiotherapy for Head and Neck Cancer
Adding nivolumab to cisplatin and radiotherapy significantly improved disease-free survival for high-risk resected LA-SCCHN. Nivolumab reduced locoregional relapses with a moderate
New Reference: FOLFOXIRI with Panitumumab for 1st Line Metastatic RAS/RAF WT Colorectal Cancer
The phase III TRIPLETE study shows that upfront mFOLFOXIRI plus panitumumab improved overall survival in patients with metastatic colorectal cancer compared to mFOLFOX plus panitum
New Reference: Erdafitinib for Cisplatin-Ineligible FGFR-Altered Metastatic Urothelial Carcinoma
Erdafitinib alone and in combination with cetrelimab demonstrated significant antitumor activity among cisplatin-ineligible patients with metastatic FGFR-altered urothelial carcino
